Table 1.
Demographic and clinical data of patients
| Patients (n = 91) | Moderate/severe MR | Trace/mild MR | |||||
|---|---|---|---|---|---|---|---|
| Group 1 (n = 8) | Group 2 (n = 16) | p | Group 3 (n = 62) | Group 4 (n = 5) | p | ||
| Age | 84 (8.25) | 85.5(7.50) | 85(10.5) | 0.55 | 84(9.5) | 80(21) | 0.32 |
| BMI (kg/m2) | 26.45 (6.01) | 23.83(3.87) | 26.44(8.10) | 0.27 | 26.67(6.14) | 27.73(6.64) | 0.82 |
| Female | 54(59.3) | 3(37.5) | 12(75) | 0.09 | 38(61.3) | 2(40) | 0.64 |
| Cardiovascular risk factors, n(%) | |||||||
| Hypertension | 75(82.4) | 5(62.5) | 13(81.3) | 0.36 | 53(86.9) | 3(60) | 0.16 |
| Diabetes | 23(25.3) | 0 | 2(12.5) | 0.53 | 20(32.8) | 0 | 0.31 |
| Dyslipidemia | 60(65.6) | 6(75) | 9(56.3) | 0.65 | 41(67.2) | 3(60) | 1.0 |
| Cardiovascular conditions, n(%) | |||||||
| PVD | 17(18.6) | 1(12.5) | 4(25) | 0.63 | 12(19.3) | 1(20) | 1.0 |
| Carotid lesion > 50% | 13(14.2) | 2(25) | 0 | 0.10 | 10(16.1) | 1(20) | 1.0 |
| PAH > 55 mm Hg | 33(36.2) | 3(37.5) | 7(43.8) | 1.0 | 19(33.8) | 3(60) | 0.32 |
| Previous stroke | 7(7.6) | 0 | 1(6.3) | 1.0 | 5(8.2) | 1(20) | 0.38 |
| CAD > 50% | 43(47.2) | 4(50) | 6(37.5) | 0.67 | 29(46.7) | 4(80) | 0.19 |
| Atrial fibrillation | 11(12.1) | 2(25) | 4(25) | 1.0 | 4(6.5) | 1(20) | 0.33 |
| NYHA, n(%) | 1.0 | 1.0 | |||||
| NYHA FC I/II | 20(22.2) | 1(12.5) | 2(12.5) | 16(25.8) | 1(20) | ||
| NYHA FC III/IV | 71(78.0) | 7 (87.5) | 14(87.5) | 46 (74.2) | 4 (80) | ||
| Non-cardiac conditions, n(%) | |||||||
| COPD | 7(7.6) | 1(12.5) | 1(6.2) | 1.0 | 3(4.8) | 2(40) | 0.04 |
| CrCl < 50 ml/min | 59(64.8) | 6(75) | 9 (56.2) | 0.65 | 40(64.5) | 2(40) | 1.0 |
| Critical illness | 3 (3.3%) | 0 | 0 | - | 2(3.23%) | 1(20%) | 0.21 |
| Risk scores | |||||||
| EuroSCORE I | 21.69(15.39) | 26.91(26.02) | 25.13(18.17) | 0.35 | 19.75(11.96) | 32.14(19.48) | 0.89 |
| EuroSCORE II | 5.7(4.23) | 8.95(9.84) | 4.91(5.23) | 0.02 | 5.63(4.31) | 6.6(4.35) | 0.63 |
| STS mortality | 5.65(4.22) | 6.06(6.79) | 4.21(5.49) | 0.14 | 5.7(3.40) | 5.36(2.23) | 0.56 |
| STS morbidity | 27.25(11.65) | 33.81(14.67) | 22.22(10.41) | 0.02 | 26.4(11.29) | 31.45(12.76) | 0.50 |
| Type of aortic prosthesis, n(%) | 0.85 | 0.07 | |||||
| Accurate | 24(26.4) | 4(50) | 5(31.3) | 12(19.4) | 3(60) | ||
| CoreValve | 35(38.5) | 2(25) | 4(25) | 26(41.9) | 2(40) | ||
| Sapien XT | 32(35.1) | 2(25) | 7(43.7) | 24(38.7) | 0 | ||
Data expressed as median (interquartile interval) or frequency (%); MR: mitral regurgitation; Group 1 - patients whose moderate/severe MR remained after transcatheter aortic valve implantation (TAVI); Group 2 - patients whose moderate/severe MR improved to trace/mild after TAVI; Group 3 - patients whose trace/mild MR remained after TAVI; Group 4 - patients whose trace/mild MR worsened to moderate/severe after TAVI; BMI: body mass index; PVD: peripheral vascular disease; PAH: pulmonary arterial hypertension; CAD: coronary artery disease; CrCl: creatinine clearance; COPD: chronic obstructive pulmonary disease; NYHA: New York Heart Association; FC: functional class; STS: Society of Thoracic Surgeons.